Nilotinib
Nilotinib
Nilotinib (pronounced: nil-oh-TIN-ib) is a type of tyrosine kinase inhibitor used in the treatment of chronic myelogenous leukemia (CML). It is marketed under the brand name Tasigna by Novartis.
Etymology
The name "Nilotinib" is derived from the chemical name Nilo-tin-ib, where "-ib" is a suffix used in drugs that are tyrosine kinase inhibitors.
Usage
Nilotinib is used to treat chronic myelogenous leukemia (CML), a type of cancer that starts in the blood-forming cells of the bone marrow. It is specifically used in cases where the disease is in the chronic phase, and the patient has not responded to or cannot tolerate other treatments, such as imatinib.
Mechanism of Action
Nilotinib works by blocking certain proteins that signal cancer cells to divide and grow. It binds to and inhibits the protein BCR-ABL, which is found in CML cells. This helps to stop or slow the spread of cancer cells.
Side Effects
Common side effects of Nilotinib include nausea, rash, itching, headache, fatigue, and diarrhea. Serious side effects can include liver damage, pancreatitis, and heart problems.
Related Terms
External links
- Medical encyclopedia article on Nilotinib
- Wikipedia's article - Nilotinib
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski